Images List Premium Download Classic

Dyslipidemia

Dyslipidemia-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Omefibrates for treating dyslipidemia and cardiovascular disease
Jiva Pharma, Inc.
November 16, 2017 - N°20170327455

The present invention relates to the fibric acid derivatives of omega-3 fatty acids and their use in treating type2 diabetes, obesity, hypertriglyceridemia, cardiovascular diseases, metabolic syndrome, cancer, alzheimer's disease; and their use for modulating activity of peroxisome proliferator-activated receptors (ppars).
Use of caspase-2 inhibitors to treat and prevent the metabolic syndrome
Duke University
November 16, 2017 - N°20170326199

Methods and compositions for treatment of obesity, insulin resistance, hyperinsulinemia, type 2 diabetes mellitus, dyslipidemia, and nonalcoholic fatty liver disease are discloses. The methods and compositions relate to inhibition of caspase-2.
Novel pentadienoyl piperidine derivative and use thereof
Snu R&db Foundation
November 09, 2017 - N°20170320825

The present invention relates to a novel pentadienoyl piperidine derivative, a pharmaceutical composition containing the same for prevention or treatment of metabolic diseases, and a functional food composition using the same for improvement or relief of metabolic diseases. The pentadienoyl piperidine derivative of the present invention inhibits the differentiation of preadipocytes, reduces body weight, visceral fat, blood lipid levels, and ...
Dyslipidemia Patent Pack
Download + patent application PDFs
Dyslipidemia Patent Applications
Download + Dyslipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dyslipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods for lipid metabolism disorder
Snu R&db Foundation
November 02, 2017 - N°20170312286

A method for inhibiting a lipid metabolism disorder of a warm-blooded animal includes administering a therapeutically effective amount of a compound being one selected from the group consisting of phosphodiesterase 5 (pde-5) inhibitors of the first type and second type and a statin analogue to a warm-blooded animal suffering from the lipid metabolism disorder. The method may treat the disease selected ...
Anti-endothelial lipase compounds and methods of using the same in the treatment and/or prevention ...
Shifa Biomedical Corporation
October 26, 2017 - N°20170305887

Endothelial lipase (el) inhibitors and methods of using such inhibitors for treating conditions implicating el are provided herein. The present invention meets the needs in the field by providing small molecule inhibitors of el function that can be used therapeutically to raise hdl cholesterol levels in blood, and can be used in the prevention and/or treatment of cholesterol and ...
Dyslipidemia therapeutic agent
Kowa Company, Ltd.
October 26, 2017 - N°20170304274

This invention provides a combination-drug composition and a combination use of pharmaceuticals for preventing and/or treating dyslipidemic conditions such as hyper-ldl cholesterolemia in mammals, including humans. This invention pertains to a drug composition for preventing and or treating dyslipidemia and the like, the drug composition including the following: (r)-2-[3-[[n-(benzoxazol-2-yl)-n-3-(4-methoxyphenoxy)propyl]...
Dyslipidemia Patent Pack
Download + patent application PDFs
Dyslipidemia Patent Applications
Download + Dyslipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dyslipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
4-(phenoxyalkyl)thio)-phenoxyacetic acids and analogs
Janssen Pharmaceutica Nv
October 26, 2017 - N°20170304254

The invention features 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs, compositions containing them, and methods of using them as ppar delta modulators to treat or inhibit the progression of, for example, dyslipidemia.
Composite preparation, containing novel 3-(4--(benzyloxy)phenyl)hex-4-inoic acid derivative and another active ...
Janssen Pharmaceutica Nv
October 19, 2017 - N°20170296539

The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases, in which a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and at least another active ingredient, which is selected from the group consisting of dipeptidyl peptidase-4 (dppiv) inhibitor-based, sulfonylurea-based, thiazolidinedione (tzd)-based, biguanide-based, and sodium/glucose cotransporter 2 (sglt2) inhibitor-based drugs, may be administered in ...
Improved sugar-depleted fruit or vegetable juice and juice-retaining fruit or vegetable derived matter, methods of ...
Janssen Pharmaceutica Nv
October 19, 2017 - N°20170296468

The present invention provides a sugar-depleted fruit or vegetable juice product, wherein said juice product is a fruit or vegetable juice or juice-retaining fruit or vegetable derived matter, wherein said juice product contains at least about 5 g/l gluconic acid and said juice product contains any two or three, of (i) at least about 0. 5 g/l ca2+, (iii) at least ...
Methods for treating hyperlipidemia with an angptl8 inhibitor and an angptl3 inhibitor
Regeneron Pharmaceuticals, Inc.
October 12, 2017 - N°20170291937

The present invention provides methods for treating patients suffering from hyperlipidaemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that ...
Growth differentiation factor 15 (gdf-15) polypeptides
Amgen Inc.
October 12, 2017 - N°20170291929

Gdf15 polypeptides, constructs comprising gdf15, and mutants thereof are provided. In various embodiments the gdf15 polypeptides, constructs comprising gdf15, and mutants thereof, can be of use in the treatment or ameliorating a metabolic disorder. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
Peptides having reduced toxicity that stimulate cholesterol efflux
The Regents Of The University Of California
October 05, 2017 - N°20170283480

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e. G., apo ai and apo e), and having high selectivity for abca1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also ...
Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (...
Amgen Inc.
September 28, 2017 - N°20170275370

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the gipr polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a glp-1 receptor agonist.
Dyslipidemia Patent Pack
Download + patent application PDFs
Dyslipidemia Patent Applications
Download + Dyslipidemia-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Dyslipidemia-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Compositions and methods for diagnosis and treatment of metabolic syndrome
United States Of America, As Represented By The Secretary Of The Navy
September 21, 2017 - N°20170266144

Compositions including an odd chain fatty acid, and salts and derivatives thereof, and methods for metabolic syndrome treatment and prophylaxis are provided, including compositions and methods for treating diabetes, obesity, hyperferritinemia, elevated insulin, glucose intolerance, dyslipidemia and related conditions. Methods for the diagnosis and monitoring of metabolic syndrome are also provided.
Fgf-8 for use in treating diseases or disorders of energy homeostasis
Technische Universität München
September 14, 2017 - N°20170258874

The present invention relates to polypeptides for use in treating diseases or disorders of energy homeostasis such as obesity, dyslipidemia, diabetes, insulin resistance, hyperglycemia or the metabolic syndrome. The invention also relates to polynucleotides encoding said polypeptides for use in treating diseases or disorders of energy homeostasis. Also provided by the present invention are pharmaceutical compositions comprising said polypeptides and ...
Methods for treating patients with hyperlipidemia by administering a pcsk9 inhibitor in combination with an ...
Regeneron Pharmaceuticals, Inc.
September 07, 2017 - N°20170253666

The present invention provides methods for treating patients suffering from hypercholesterolemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that ...
Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their ...
Regeneron Pharmaceuticals, Inc.
August 31, 2017 - N°20170246227

The present invention relates to the combination of spirulina and palmitoylethanolamide (pea) and/or pharmaceutically acceptable derivates or salts thereof, pharmaceutical formulations comprising the combination of spirulina and pea and/or pharmaceutically acceptable derivates or salts thereof, optionally together with at least one physiologically acceptable excipient, and the use of the combination of spirulina and pea and/or pharmaceutically acceptable ...
Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations
Ionis Pharmaceuticals, Inc.
August 17, 2017 - N°20170233732

Provided herein are methods, compounds, and compositions for reducing expression of apociii mrna and protein in a patient with fredrickson type i dyslipidemia, fcs, lpld. Also provided herein are methods, compounds, and compositions for treating, preventing, delaying, or ameliorating fredrickson type i dyslipidemia, fcs, lpld, in a patient. Further provided herein are methods, compounds, and compositions for increasing hdl levels ...
Piperazine derivatives as liver x receptor modulators
Vitae Pharmaceuticals, Inc.
August 10, 2017 - N°20170226067

Provided are novel compounds of formula (i): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are liver x receptor modulators, and which are useful in the treatment of diseases and disorders associated with the liver x receptor. Also provided are the compounds of formula (i) and pharmaceutical compositions thereof for treating atherosclerosis, cardiovascular disease, alzheimer's disease, dermatitis, dyslipidemia, cancer ...
Methods for reducing ldl-cholesterol
Rinat Neuroscience Corp.
August 10, 2017 - N°20170224816

The present invention relates to methods for the treatment of reducing ldl-cholesterol levels in a subject infected with hepatitis c virus (hcv) or at high risk of contracting hcv comprising administration to the subject in need thereof a therapeutically effective amount of an antagonist antibody which specifically binds to a human pcsk9 protein. The subject treatment can be used in ...
[7,6]-fused bicyclic antidiabetic compounds
Merck Sharp & Dohme Corp.
August 03, 2017 - N°20170217942

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated ...
Loading